ClinicalTrials.gov
ClinicalTrials.gov Menu

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00758862
Recruitment Status : Completed
First Posted : September 25, 2008
Results First Posted : July 23, 2018
Last Update Posted : July 23, 2018
Sponsor:
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:
A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic Lesions (SITL). A total of 20 patients will be enrolled.

Condition or disease Intervention/treatment Phase
Secondarily Infected Traumatic Lesions (SITL) Impetigo Drug: 2% TD1414 Cream Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
Study Start Date : December 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Impetigo

Arm Intervention/treatment
Experimental: 1 Drug: 2% TD1414 Cream
Application 3 times daily for 7 days




Primary Outcome Measures :
  1. TD1414 Serum Concentration by Timepoint [ Time Frame: From 0 hours to 240 hours ]
    On Days 1 and 2(and possibly Day 3 depending on the time of first application on Day 1) a sample was taken for pharmacokinetic(PK) analysis at any time before first application on Day 1, and at 12±1, 18±1, 24±1 and 36±4 hours after first application. If the 36±4 hours sampling time fell on Day 3, then a second sample was also required on Day 3, but was to be obtained at 6pm or afterwards. On Days 3 to 6(and also Day 7 if the very last application fell on Day 8), one sample was taken on each day at any time during the day. On Days 7 and 8(or Days 8 and 9 if very last application was on Day 8), a sample was taken immediately before the very last application and at 6±1, 12±1 and 24±2 hours after the very last application. On Days 9 and 10, one sample was taken on each day at any time during the day. If the participant had already had a sample(s) taken on Day 9 because the timing of some of the post-last application samples fell on this day, then further samples were not required on Day 9

  2. Peak TD1414 Serum Concentration (Cmax ) [ Time Frame: From 0 hours to 240 hours ]

    The Cmax was summarised by lesion size at baseline, by SIRS scores at baseline and by amount of TD1414 cream used.

    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. For description of lesion size, SIRS score and amount of TD1414 cream used please see outcome measure 3, 4 and 5 respectively.


  3. Peak Serum Concentration by Baseline Lesion Size [ Time Frame: From 0 hours to 240 hours ]

    On Day 1 (before the first application), the (sub)investigator recorded the size of the lesion(s). For each participant the size of the lesion was allocated to one of two categories: ≤15cm² or >15cm². The Cmax is presented by baseline lesion size category (≤15 cm² and >15 cm²).

    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.


  4. Peak Serum Concentration by SIRS Score [ Time Frame: From 0 hours to 240 hours ]

    On Day 1 (before the first application), the (sub)investigator recorded the severity of the lesion(s).

    The severity was to be recorded using the Severity of Infection Rating Scale (SIRS).

    For the SIRS, the following seven clinical signs/symptoms of infection were assessed:

    Exudates/pus Crusting Erythema Oedema Tissue warmth Itching Pain

    Each of the seven signs/symptoms was scored using the following scale:

    0 = absent 2 = mild 4 = moderate 6 = severe The scores for each sign/symptom were summed to give the total SIRS score. The total SIRS score could range from 0 to 42.

    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.


  5. Peak Serum Concentration by Amount of TD1414 Cream Used [ Time Frame: From 0 hours to 240 hours ]

    The weight of TD1414 cream used was calculated by subtracting the weight of the used dispensed tube from the mean weight of a full tube.

    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.


  6. Time to Reach Peak Serum Concentration (Tmax ) [ Time Frame: From 0 hours to 240 hours ]
    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.

  7. Time to Reach Peak Serum Concentration (Tmax ) by Baseline Lesion Size [ Time Frame: From 0 hours to 240 hours ]
    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.

  8. Time to Reach Peak Serum Concentration (Tmax ) by SIRS Score [ Time Frame: From 0 hours to 240 hours ]
    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.

  9. Time to Reach Peak Serum Concentration (Tmax ) by Amount of TD1414 Cream Used [ Time Frame: From 0 hours to 240 hours ]
    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.

  10. Area Under the Curve (AUC(0-t)) [ Time Frame: From 0 hours to 240 hours ]

    Area under the concentration-time curve (AUC(0-t)) from time 0 to time of last non-zero observation after dosing, calculated by linear/log trapezoidal method.

    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.


  11. Area Under the Curve by Baseline Lesion Size [ Time Frame: From 0 hours to 240 hours ]

    On Day 1 (before the first application), the (sub)investigator recorded the size of the lesion(s). For each participant the size of the lesion was allocated to one of two categories: ≤15cm² or >15cm².

    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.


  12. Area Under the Curve by SIRS Score [ Time Frame: From 0 hours to 240 hours ]

    On Day 1 (before the first application), the (sub)investigator recorded the severity of the lesion(s).

    The severity was to be recorded using the Severity of Infection Rating Scale (SIRS).

    For the SIRS, the following seven clinical signs/symptoms of infection were assessed:

    Exudates/pus, Crusting, Erythema, Oedema, Tissue warmth, Itching and Pain.

    Each of the seven signs/symptoms was scored using the following scale:

    0 = absent 2 = mild 4 = moderate 6 = severe

    The scores for each sign/symptom were summed to give the total SIRS score. The total SIRS score could range from 0 to 42.

    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.


  13. Area Under the Curve (AUC(0-t)) by Amount of TD1414 Cream Used [ Time Frame: From 0 hours to 240 hours ]

    The weight of TD1414 cream used was calculated by subtracting the weight of the used dispensed tube from the mean weight of a full tube.

    Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability and willingness to comply with all the study requirements/procedures
  • Age ≥ 18 and ≤65 years
  • Primary bullous/non-bullous impetigo or SITL
  • Patients suffering from primary bullous/non-bullous impetigo must have:

    • Not more than 10 discrete lesions, and
    • A total lesional area ≥ 1 cm2 and ≤ 100 cm2, and
    • Any surrounding erythema must not extend beyond 2 cm from the edge of the lesion, and
    • Total SIRS score equal to or ≥ 8
  • Patients suffering from SITL must have:

    • A total infected area of the traumatic lesion ≥ 1 cm2 and ≤ 100 cm2, and
    • Any surrounding erythema must not extend beyond 2 cm from the edge of the lesion, and
    • Total SIRS score ≥ 8, and
    • SITL not caused by burns or animal/human bite
  • Amenable for treatment with topical antibiotic alone
  • Body Mass Index ≥18 and ≤ 35 kg/m2.

Exclusion Criteria:

  • Immunosuppressed state or other serious systemic disease
  • Signs and/or symptoms of systemic infection, such as malaise and fever or local adenopathy and fever
  • Unwillingness to abstain from use of any other topical products including emollients on the lesional area during the study
  • Systemic treatment with antibacterials or immunosuppressive agents (e.g. corticosteroids) within 2 days before day 1 (inhaled/intranasal steroids may be used)
  • Topical treatment with antibacterials, immunosuppressive agents (e.g. corticosteroids) or antiseptics (e.g. alcohol, chlorhexidine, hydrogen peroxide, iodine) on the lesional area within 2 days before day 1
  • Indication for surgical or systemic treatment of the SITL/impetigo
  • Known or suspected hypersensitivity to any of the components of the study medication
  • Participation in any other interventional clinical trial or use of an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to day 1
  • Previously enrolled in this study
  • A blood alcohol content ≥ 0.08% as determined by a Breathalyzer test
  • Known or suspected history of alcohol abuse/alcoholism or drug abuse
  • Known or suspected impairment of liver function
  • Heart rhythm disturbances or clinically significant quantitative or qualitative abnormality in the pretreatment ECG
  • Blood donation in excess of 500mL within 56 days before day 1 or donation during the study or within 3 days of leaving the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00758862


Locations
United States, Texas
J&S Studies, Inc.
College Station, Texas, United States, 77840
Sponsors and Collaborators
LEO Pharma
Investigators
Principal Investigator: Terry Jones, MD J&S Studies Inc.

Responsible Party: LEO Pharma
ClinicalTrials.gov Identifier: NCT00758862     History of Changes
Other Study ID Numbers: TD1414-C22
First Posted: September 25, 2008    Key Record Dates
Results First Posted: July 23, 2018
Last Update Posted: July 23, 2018
Last Verified: June 2018

Additional relevant MeSH terms:
Impetigo
Staphylococcal Skin Infections
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Streptococcal Infections
Skin Diseases, Bacterial
Skin Diseases, Infectious
Infection
Skin Diseases